Skip to main navigation
Ventyx Biosciences, Inc. Ventyx Biosciences, Inc.
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Advisory Board
    • Contact
  • Science
  • Pipeline
    • Overview
    • VTX958
    • VTX002
    • VTX2735
    • VTX3232
  • Investors
    • Overview
    • News & events
    • Stock information
    • Governance
    • Financials & filings
    • IR resources
  • Careers
  • News Releases
  • Events
  • Presentations

News Releases

News Releases

June 7, 2023
Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis
Read more
May 31, 2023
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Read more
May 11, 2023
Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
Read more
May 4, 2023
Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023
Read more
March 24, 2023
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Read more
March 23, 2023
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
Read more
March 15, 2023
Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
Read more
March 11, 2023
Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure
Read more
February 28, 2023
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Read more
January 26, 2023
Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
Read more
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Page 5
  • Next page ›
  • Last page »
Displaying 11 - 20 of 45


Email Alerts


FAQ


Contact IR


RSS Feeds
Contact us
info@ventyxbio.com
  • Privacy Policy
  • Terms Of Use
© 2023 Ventyx Biosciences, Inc. All rights reserved.
linkedin
Ventyx Biosciences, Inc.